Yasuyuki Okuda

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · The Lancet Oncology · 2021 · 392 citations

Oncology, Gastrointestinal Oncology, Colorectal Cancer +5

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)

Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata et al. · Clinical Journal of the American Society of Nephrology · 2020 · 210 citations · Full text

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

Sadayoshi Ito, Hiroshi Itoh, Hiromi Rakugi et al. · Hypertension · 2019 · 176 citations · Full text

Morning Home Blood Pressure Is a Strong Predictor of Coronary Artery Disease

Kazuomi Kario, Ikuo Saito, Toshio Kushiro et al. · Journal of the American College of Cardiology · 2016 · 175 citations · Full text

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav et al. · Nature Communications · 2023 · 138 citations · Full text